Additional file 6: of Quartz-Seq2: a high-throughput single-cell RNA-sequencing method that effectively uses limited sequence reads

Table S5. Buffer composition for the poly-tailing step. (XLSX 33 kb

Additional file 3: of Quartz-Seq2: a high-throughput single-cell RNA-sequencing method that effectively uses limited sequence reads

Table S2. Differentially expressed genes between clusters 1 and 8. (XLSX 85 kb

Additional file 2: of Quartz-Seq2: a high-throughput single-cell RNA-sequencing method that effectively uses limited sequence reads

Table S1. Cost calculation for Quartz-seq2. (XLSX 97 kb

Additional file 4: of Quartz-Seq2: a high-throughput single-cell RNA-sequencing method that effectively uses limited sequence reads

Table S3. Enrichment analysis of biological pathways using the genes differentially expressed between clusters 1 and 8. (XLSX 404 kb

Additional file 5: of Quartz-Seq2: a high-throughput single-cell RNA-sequencing method that effectively uses limited sequence reads

Table S4. Primer sequences. (XLSX 148 kb

Additional file 1: of Quartz-Seq2: a high-throughput single-cell RNA-sequencing method that effectively uses limited sequence reads

Supplemental note and supplemental figures. (PDF 12818 kb

Changes in the proportion of Y93H RAV within each individual.

<p>The proportion of Y93H RAV over the Y93 wild type within each patient was determined by deep sequencing at baseline and at an early time point during SMV/PR therapy (within 7 days). The mean proportion of Y93H RAV was 52.7% at baseline and 29.7% during therapy (p = 0.023). The proportion of Y93H was reduced in 21 of 29 cases (72.4%, solid lines). In contrast, Y93H percentages increased in 8 cases (27.6%, broken lines).</p

HCV RNA reduction of Y93H RAV versus the Y93 wild type during SMV/PR therapy.

<p>Reduction of HCV RNA from baseline to an early time point during SMV/PR therapy was determined for Y93H RAV and the Y93 wild type. Within 7 days of the initiation of therapy, HCV RNA reduction was significantly greater for Y93H RAV (-3.7 ± 1.3 logIU/mL/day) than the Y93 wild type (-3.4 ± 1.0 logIU/mL/day) (p<0.001).</p

Factors associated with rapid fibrosis progression.

<p>Factors associated with rapid fibrosis progression.</p

Detection of Y93H RAV by direct sequencing at baseline and during SMV/PR therapy.

<p>BT, breakthrough;</p><p>SVR, sustained virological response</p><p>*within 7 days of the initiation of treatment, when HCV RNA was still detectable,</p><p>**at least 3 months after the end of treatment</p><p>Detection of Y93H RAV by direct sequencing at baseline and during SMV/PR therapy.</p